Physician profile
Maurice Johnson
NPI 1689751497
$1,960.06
in general payments reported to CMS, 2019-2025
23 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $235 · 2021: $14.20 · 2022: $367 · 2023: $17.95 · 2024: $387 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $280.32 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $236.51 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $194.91 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $187.66 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.02 | 2019-2025 | Jardiance |
| Pfizer INC. | $125.46 | 2022-2025 | |
| Glaxosmithkline, LLC. | $121.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $113.40 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $107.52 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.53 | 2022-2024 | |
| Abbott Laboratories | $61.32 | 2019-2022 | |
| Amarin Pharma, INC. | $41.82 | 2019 | |
| Indivior INC. | $36.91 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $33.19 | 2019-2024 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $28.30 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.92 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.87 | 2020 | |
| Amgen INC. | $20.58 | 2024 | Otezla, Repatha |
| Ironwood Pharmaceuticals, INC | $17.67 | 2020 | |
| Mylan Specialty L.P. | $16.60 | 2019 | |
| Orexo US, INC. | $15.88 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.98 | 2022 | |
| Circassia INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.